Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol

Journal of Diabetes

Volumn 6, Issue 4, 2014, Pages 378-380

  Balis, Dainius A ^a   Tong, Cindy ^a   Meininger, Gary ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

1,5 anhydroglucitol; Canagliflozin; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

1,5 ANHYDROSORBITOL; CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; 1,5-ANHYDROGLUCITOL; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ALCOHOL ANALYZER; ARTICLE; CARBOHYDRATE ANALYSIS; ENZYMATIC ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; FOLLOW UP; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PROGNOSIS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84901845056     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12116     Document Type: Article

References (13)

1. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1, 5-anhydroglucitol (GlycoMark): A short-term glycemic marker. Diabetes Technol Ther. 2003; 5: 355-363.
2. McGill JB, Cole TG, Nowatzke W etal. Circulating 1, 5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: A U.S. trial of the GlycoMark assay. Diabetes Care. 2004; 27: 1859-1865.
3. GlycoMark, Inc. GlycoMark®, for the Quantitative Measurement of 1, 5-Anhydroglucitol (1, 5AG) in Serum Or Plasma [Package Insert]. GlycoMark, Inc., New York, 2013.
4. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005; 22: 980-985.
5. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32: 515-531.
6. Janssen Pharmaceuticals. INVOKANA™ (Canagliflozin) Tablets, for Oral Use [Package Insert]. Janssen Pharmaceuticals, Titusville, NJ, 2013.
7. Stenlöf K, Cefalu WT, Kim K-A etal. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15: 372-382.
8. Wilding JP, Charpentier G, Hollander P etal. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract. 2013; 67: 1267-1282.
9. Lavalle-Gonzalez F, Januszewicz A, Davidson J etal. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia. 2013; 56: 2582-2592.
10. Cefalu WT, Leiter LA, Yoon K-H etal. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382: 941-950.
11. Schernthaner G, Gross JL, Rosenstock J etal. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial. Diabetes Care. 2013; 36: 2508-2515.
12. Yale JF, Bakris G, Cariou B etal. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013; 15: 463-473.
13. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract. 2013; 41: 72-84.